Publication
Inhibition of mutated, activated BRAF in metastatic melanoma.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (4)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 4
- cancerMelanomacivic_curation1.00
- drugVemurafenibcivic_curation1.00
- geneBRAFcivic_curation1.00
- variantBRAF V600Ecivic_curation1.00
Curated evidence
Evidence citing this paper (3)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 20818844
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| BRAF D594N1 | ||||||||
| Dabrafenib | Cutaneous MelanomaALIAS | Predictive | D | Supports Sensitivity Response | — | rejected | EID2815Acquired resistance to vemurafenib in BRAF-V600E positive melanomas frequently confound vemurafenib therapy. Proposed resistance mechanisms include PDGFRbeta upregulation or NRAS mutations resulting i… (full text at CIViC) PMID 20818844 · Flaherty et al., 2010 · Open in CIViC | civic |
| BRAF V600E2 | ||||||||
| Dabrafenib | Melanoma | Predictive | D | Supports Sensitivity Response | — | submitted | EID2127Acquired resistance to vemurafenib in BRAF-V600E positive melanomas frequently confound vemurafenib therapy. PMID 20818844 · Flaherty et al., 2010 · Open in CIViC | civic |
| Vemurafenib | Melanoma | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID1749Multicenter, phase 1, dose-escalation trial of PLX4032 (Vemurafenib). Treatment of metastatic melanoma with PLX4032 in patients with tumors that carry the V600E BRAF mutation resulted in complete or p… (full text at CIViC) PMID 20818844 · Flaherty et al., 2010 · Open in CIViC | civic |